Leadartis announces its partnership in the TERET project.


Leadartis is proud to announce its participation as a partner in the TERET project (New Treatments for Degenerative Retina Diseases) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS of the society program. The MINECO’s participation demonstrates its support of Leadartis technology research and main objectives.

The aim of the TERET project is to support the experimental development of the next generation of blockers for the angiogenesis market including cancer and Wet Age-related Macular Degeneration (AMD) where it is essential to develop new compounds with greater efficacy and reduced number of injections without compromising eye visual acuity of the patients. Leadartis will use its proprietary Trimerbody® technology to generate the fully human angiogenesis inhibitor.

LeadArtis is one of the leading companies aiming to bring to the market products relying on cancer immunotherapy and anti angiogenesis based therapies by means of its antibody engineering technology, Trimerbody®. Despite recent advances in the field, most of the current initiatives are still early stage and exploratory. Whereas most of current immune-checkpoint blockers in development are conventional monoclonal antibodies (mAbs); comparatively, recombinant antibody technologies are strongly positioned and shortly will become preferred. The added value of this alternative antibody format is comprising up to six valences, mono/multispecificity, small size & manufacturing ease which can be taken advantage of to generate more effective compounds and, provided that we can work on highly validated mechanisms of action, with lower risk of unwanted adverse events.

     LeadArtis news image              LeadArtis news image    


Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...